

10 Rest 10 28 SEP 2001

PATENT

10 Rest 10 28 SEP 2001
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
MALLET ET AL.

Examiner: UNASSIGNED

Art Unit: UNASSIGNED

Serial No.: 09/831,335

Filed: **MAY 8, 2001**

Title: **NOVEL SYSTEM FOR REGULATING
TRANSGENE EXPRESSION**

I hereby certify that this correspondence is being
deposited with the United States Postal Service as ~~First~~ **Express**
Class Mail in an envelope addressed to Commissioner
for Patents, Washington, D.C. 20231, on

9/28/01 **EL 749687/81 US**
Date of Deposit **EXPRESS MAIL NO.**

D. Kapadia
Signature


STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE
COPIES PURSUANT TO 37 C.F.R. 1.821 (f)

Commissioner for Patents
Washington, D.C. 20231

Sir:

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the enclosed substitute pages of the "Sequence Listing" and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same; and (2) the content of the substitute copy of the Sequence Listing and the computer readable copies required by 37 C.F.R. 1.821 (e) contain no new matter. Support for the Amendments can be found in the application as filed.

Respectfully submitted,


William C. Coppola, Reg. No. 41,686
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-4854
Telefax (908) 231-2626

Docket No. ST98036-US